» Articles » PMID: 27022291

Impact of the Care Provided by Gynecologic Oncologists on Outcomes of Cervical Cancer Patients Treated with Radical Hysterectomy

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2016 Mar 30
PMID 27022291
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

For many malignant diseases, specialized care has been reported to be associated with better outcomes. The purpose of this study is to investigate the influence of gynecologic oncologists on treatment outcomes for cervical cancer patients treated by radical hysterectomy. Records of patients who received radical hysterectomy between January 2005 and June 2010 were reviewed. Perioperative morbidity, recurrence-free survival, and cancer-specific survival were assessed. Cox regression model was used to evaluate gynecologic oncologists as an independent predictor of survival. A total of 839 patients were included. Of these patients, 553 were treated by gynecologic oncologists, while 286 were treated by other subspecialties. With regard to operative outcomes, significant differences in favor of operation by gynecologic oncologists were found in number of patients receiving para-aortic node sampling and dissection (P=0.038), compliance with surgical guidelines (P=0.003), operative time (P<0.0001), estimated blood loss (P<0.0001), transfusion rate (P=0.046), number of removed nodes (P=0.033), and incidences of ureteric injury (P=0.027), cystotomy (P=0.038), and fistula formation (P=0.002). Patients who were operated on by gynecologic oncologists had longer recurrence-free survival (P=0.001; hazard ratio [HR] =0.64; 95% confidence interval [CI] [0.48, 0.84]) and cancer-specific survival (P=0.005; HR=0.64; 95% CI [0.47, 0.87]), and this association remained significant in patients with locally advanced disease. Care by gynecologic oncologists was an independent predictor for improved recurrence-free survival (P<0.0001; HR=0.57; 95% CI [0.42, 0.76]) and cancer-specific survival (P=0.001; HR=0.58; 95% CI [0.42, 0.81]), which was still significant among patients with locally advanced cancer. Given the results, we believe for cervical cancer patients receiving radical hysterectomy, operation by gynecologic oncologists results in significantly improved surgical and survival outcomes. The importance of the subspecialty of a gynecologist for cervical cancer patients should be addressed in clinical practice, especially for those in developing countries.

Citing Articles

Prognostic value of lymphovascular space invasion in stage IA to IIB cervical cancer: A meta-analysis.

Huang Y, Wen W, Li X, Xu D, Liu L Medicine (Baltimore). 2023; 102(15):e33547.

PMID: 37058045 PMC: 10101290. DOI: 10.1097/MD.0000000000033547.


Assessment of ESGO Quality Indicators in Cervical Cancer Surgery: A Real-World Study in a High-Volume Chinese Hospital.

Ding Y, Zhang X, Qiu J, Zhang J, Hua K Front Oncol. 2022; 12:802433.

PMID: 35145915 PMC: 8821940. DOI: 10.3389/fonc.2022.802433.


Surveillance of radical hysterectomy for early-stage cervical cancer in the early experienced period of minimally invasive surgery in Japan.

Ohta T, Nagase S, Okui Y, Enomoto T, Yamagami W, Mikami M Int J Clin Oncol. 2021; 26(12):2318-2330.

PMID: 34435284 DOI: 10.1007/s10147-021-02017-4.


Treatment Outcomes of Early Carcinoma Cervix Before and After Sub-specialization.

Thomas V, Chandy R, Sebastian A, Thomas A, Thomas D, Ram T Indian J Surg Oncol. 2021; 12(1):78-85.

PMID: 33814836 PMC: 7960842. DOI: 10.1007/s13193-020-01228-x.


Morbidity after surgical management of cervical cancer in low and middle income countries: A systematic review and meta-analysis.

Allanson E, Powell A, Bulsara M, Lee H, Denny L, Leung Y PLoS One. 2019; 14(7):e0217775.

PMID: 31269024 PMC: 6608935. DOI: 10.1371/journal.pone.0217775.


References
1.
Read T, Myerson R, Fleshman J, Fry R, Birnbaum E, Walz B . Surgeon specialty is associated with outcome in rectal cancer treatment. Dis Colon Rectum. 2002; 45(7):904-14. DOI: 10.1007/s10350-004-6327-5. View

2.
Zanetta G, Colombo A, Milani R, Placa F, Mangioni C . Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin c, cis-platin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA. Int J Gynecol Cancer. 1995; 5(1):40-44. DOI: 10.1046/j.1525-1438.1995.05010040.x. View

3.
Lentz S, Muderspach L, Felix J, Ye W, Groshen S, Amezcua C . Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients. Obstet Gynecol. 2004; 103(6):1204-10. DOI: 10.1097/01.AOG.0000125869.78251.5e. View

4.
Robova H, Halaska M, Pluta M, Skapa P, Strnad P, Lisy J . The role of neoadjuvant chemotherapy and surgery in cervical cancer. Int J Gynecol Cancer. 2010; 20(11 Suppl 2):S42-6. DOI: 10.1111/igc.0b013e3181f60d73. View

5.
Zullo M, Manci N, Angioli R, Muzii L, Benedetti Panici P . Vesical dysfunctions after radical hysterectomy for cervical cancer: a critical review. Crit Rev Oncol Hematol. 2003; 48(3):287-93. DOI: 10.1016/s1040-8428(03)00125-2. View